Open Nav

Please submit your session questions in advance at

Landos Biopharma

  • Josep Bassaganya-Riera, Landos Biopharma

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, gut-restricted small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD), has completed Phase 1 clinical testing and initiated Phase 2 clinical trials for Crohn's and ulcerative colitis. Landos is advancing a robust pipeline of new compounds for other autoimmune diseases, some of which will advance to IND in 2019.

  • Date:Monday, February 11
  • Time:11:00 AM - 11:15 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Submission ID:23299
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Provide an update on Landos clinical development program for Crohn's and ulcerative colitis.
  • Company
  • Company HQ City:Blacksburg
  • Company HQ State:Virginia
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$10M
  • Size of Last Investment Round:$10M
  • Previous and Current Investors:Perceptive Advisors
  • CEO/Top Company Official:Dr. Josep Bassaganya-Riera
  • Year Founded:2017
  • Main Therapeutic Focus:Gastrointestinal
  • Lead Product in Development:BT-11
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
Josep Bassaganya-Riera
Landos Biopharma